SCHEMBL6206860

SCHEMBL6206860

NCc1ccccc1F.c1ccc2c(c1)CCC2

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 3/20 0.50
NPC1 O15118 2/20 0.46
RAB9A P51151 2/20 0.46
TSHR P16473 1/20 0.44
IDO1 P14902 2/20 0.42
ALDH1A1 P00352 2/20 0.42
MAOB P27338 4/20 0.41
PNMT P11086 2/20 0.41
AOC3 Q16853 1/20 0.38
LOXL2 Q9Y4K0 1/20 0.37
KDM1A O60341 1/20 0.36
MAOA P21397 1/20 0.36
CYP2A13 Q16696 1/20 0.36
NCF1 P14598 1/20 0.36
TP53 P04637 1/20 0.36
MAPT P10636 1/20 0.36
NFKB1 P19838 1/20 0.36
HTT P42858 1/20 0.36
NFKB2 Q00653 1/20 0.36
RELA Q04206 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30556230 0.83
SCHEMBL6621 0.83
SCHEMBL29257301 0.81 TAAR1 (0.65) TAAR1IDO1ALDH1A1MAOBPNMT
Hydrochloric Acid SCHEMBL6926750 0.81 TAAR1 (0.65) TAAR1IDO1ALDH1A1MAOBPNMT
Bromide SCHEMBL31513719 0.81 TAAR1 (0.65) TAAR1IDO1ALDH1A1MAOBPNMT
Propylamine SCHEMBL6559405 0.73 TSHR (0.55) TSHRALDH1A1MAOBMAOA
SCHEMBL10535124 0.72 PNMT (0.52) TSHRALDH1A1PNMTHTTSMN1; SMN2
Benzylamine SCHEMBL7398997 0.71 LOXL2 (0.64) TAAR1NPC1RAB9ATSHRMAOB
SCHEMBL23005039 0.71 TAAR1 (0.71) TAAR1IDO1MAOBPNMTAOC3
Hydrazine SCHEMBL2172540 0.71 TSHR (0.75) TSHRIDO1MAOBPNMTMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1487798-A4 SUBSTITUTED TETRAHYDROISOQUINOLINES AS C5A RECEPTOR MODULATORS NEUROGEN CORP (US) 2005-07-13 EP disclosed
US-6916830-B2 Substituted tetrahydroisoquinolines as C5a receptor modulators NEUROGEN CORPORATION (US) 2005-07-12 US disclosed
EP-1487798-A1 SUBSTITUTED TETRAHYDROISOQUINOLINES AS C5A RECEPTOR MODULATORS Neurogen Corporation (US) 2004-12-22 EP disclosed
US-20040204446-A1 Nitrogen compounds such as N-(2-Fluoro-benzyl)-N-indan-2-yl-2-(3-methyl-2-o-tolyl-piperidin-1-yl) -acetamide, administered for prophylaxis arthritis, psoriasis, cardiovascular disorders, reperfusion injury or respiratory system disorders NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2004-10-14 US disclosed
US-6777422-B2 FOR TREATING A VARIETY OF INFLAMMATORY AND IMMUNE SYSTEM DISORDERS NEUROGEN CORP. 2004-08-17 US disclosed
US-20040006069-A1 Substituted tetrahydroisoquinolines as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2004-01-08 US disclosed
WO-2003082828-A1 SUBSTITUTED TETRAHYDROISOQUINOLINES AS C5A RECEPTOR MODULATORS NEUROGEN CORPORATION (US) 2003-10-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040006069-A1 Substituted tetrahydroisoquinolines as C5a receptor modulators C5AR1, C3AR1, C5AR2 TAAR1 286/4885NPC1 2523/4885RAB9A 1068/4885
US-20040204446-A1 Nitrogen compounds such as N-(2-Fluoro-benzyl)-N-indan-2-yl-2-(3-methyl-2-o-tolyl-piperidin-1-yl) -acetamide, administered for prophylaxis arthritis, psoriasis, cardiovascular disorders, reperfusion injury or respiratory system disorders C5AR1, C3AR1, C5AR2 TAAR1 218/4885NPC1 2062/4885RAB9A 2127/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.